MOSCOW (MRC) -- The European Parliament says that the EU should become more self-sufficient in medicines and medical equipment so that affordable treatments are available at any time, said Chemweek.
It calls for priority to be given to boosting domestic production of essential and strategic medicines because currently 40% of medicines marketed in the EU originate in non-EU countries and 60-80% of its active pharmaceutical ingredient (API) supplies are produced in China and India.
The COVID-19 health crisis has emphasized the need to return API production to Europe and the EU Parliament has welcomed the EU health program EU4Health, which it says has the potential to ensure safe medicines in Europe can be made available, accessible, and affordable. Meanwhile, members of the European Parliament have asked the European Commission to examine ways to restore pharmaceutical manufacturing in Europe, as part of the EU4Health strategy.
Cefic welcomed the EU4Health program in July because it supports the relaunch of the EU's production of APIs and strengthens procurement of vital medicines, medical devices, and personal protective equipment. EU4Health is a dedicated funding program for 2021-27 to build resilient health systems in the EU that includes investments of EUR9.4 billion (USD11.1 billion), the Commission says.
According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.